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1. Introduction 
Sexually transmitted infections (STIs) are infections that are spread primarily through 
person-to-person sexual contact. During the past two decades, STDs have undergone a 
dramatic transformation. First, the change in name from venereal diseases (V.D.) to sexually 
transmitted diseases (STD) indicates this transformation. The term “venereal” as it relates to 
disease dates back to 15th century. Its root comes from the Latin venereus or venus, meaning 
“from sexual love or desire.” Secondly, attention is now given not only to specific sexually 
transmitted microbial agents, but also to clinical syndromes associated with STDs as 
follows: 
 urethral discharge 
 genital ulcers 
 inguinal swellings (bubo, which is a swelling in the groin) 
 scrotal swelling 
 vaginal discharge 
 lower abdominal pain 
 neonatal eye infections (conjunctivitis of the newborn). 
There are more than 30 different sexually transmissible bacteria, viruses and parasites 
pathogenic to man. Some of the most common are listed below: 
1.1 Bacteria infections 
i. Neisseria gonorrhoeae, causes gonorrhoea or gonococcal infection 
ii. Chlamydia trachomatis, causes chlamydial infections 
iii. Treponema pallidum, causes syphilis 
iv. Haemophilus ducreyi, causes chancroid 
v. Klebsiella granulomatis, previously known as Calymmatobacterium granulomatis causes 
granuloma inguinale or donovanosis. 
1.2 Viruses 
i. Human immunodeficiency virus, causes AIDS 
ii. Herpes simplex virus (HSV) type 1 & 2 causes genital herpes. 
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iii. Human papillomavirus (HPV )causes genital warts and certain subtypes lead to 
cervical cancer in women. 
iv. Hepatitis B virus, Hepatitis C virus causes hepatitis and chronic cases may lead to 
cancer of the liver. 
v. Molluscum contagiosum virus (member of poxvirus family), causes molluscum 
contagiosum virus. 
1.3 Parasite 
i. Trichomonas vaginalis, causes vaginal trichomoniasis. 
1.4 Fungal agents 
i. Candida albicans,causes vulvovaginitis in women; inflammation of the glans penis and 
foreskin in men. 
1.5 Ectoparasites 
i. Phthirus pubis 
ii. Sarcoptes scabiei 
Sexually transmitted diseases are divided into "traditional" or "first generation" STD 
(syphilis, gonorrhoea, chancroid) and "second generation" STD (Chlamydia infections and 
Virus infections) (Temmerman, 1992). Although many different pathogens cause STIs, 
some display similar or overlapping signs (what the individual or the health-care 
provider sees on examination) and symptoms (what the patient feels such as pain or 
irritation). Some of these signs and symptoms are easily recognizable and consistent, 
giving what is known as a syndrome that signals the presence of one or a number of 
pathogens. For example, a discharge from the urethra in men can be caused by 
gonorrhoea alone, chlamydia alone or both together. A matter of serious concern is the 
emergence of antimicrobial resistance to sexually transmitted microbial agents (e.g., 
penicillinase-producing strains of gonococci) since the late 1970s which is posing a serious 
barrier to patient care. 
2. Significance of STI’s 
The true incidence of STDs is not known, because of inadequate reporting due to secrecy 
that surrounds these infections. The “second generation” STDs are tending to replace the 
first generation i.e. classical bacterial diseases (syphilis, gonorrhoea and chancroid). In many 
industrialized countries, the incidence of genital C. trachomatis infection exceeds that of 
gonococcal infection.  
According to 2005 WHO estimates, 448 million new cases of curable STIs (syphilis, 
gonorrhoea, chlamydia and trichomoniasis) occur annually throughout the world in adults 
aged 15-49 years (WHO fact sheet 2011). This does not include HIV and other STIs which 
continue to adversely affect the lives of individuals and communities worldwide. In 
developing countries, STIs and their complications rank in the top five disease categories for 
which adults seek health care. Some STIs are asymptomatic and it is reported that up to 70% 
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of women and a significant proportion of men with gonococcal and/or chlamydial 
infections experience no symptoms at all. Both symptomatic and asymptomatic infections 
can lead to the development of serious complications, as follows. 
2.1 STIs adversely affect the health of women 
Untreated STIs can have critical implications for reproductive, maternal and newborn 
health. STIs are the main preventable cause of infertility, particularly in women. It is 
observed that 10 - 40% of women with untreated chlamydial infection develop symptomatic 
pelvic inflammatory disease. Post-infection tubal damage is responsible for 30 - 40% of cases 
of female infertility (Pellati et al., 2008). Furthermore, women who have had pelvic 
inflammatory disease are 6 - 10 times more likely to develop an ectopic (tubal) pregnancy 
than those who have not, and 40 - 50% of ectopic pregnancies can be attributed to previous 
pelvic inflammatory disease (Clark and Baranyai, 1987; Svenstrup et al., 2008). Infection 
with certain types of the human papillomavirus can lead to the development of genital 
cancers, particularly cervical cancer in women. 
2.2 STIs and adverse outcomes of pregnancy 
Untreated STIs are associated with congenital and perinatal infections in neonates, 
particularly in regions where rates of infection remain high. In pregnant women with 
untreated early syphilis, 25% of pregnancies result in stillbirth and 14% in neonatal death – 
an overall perinatal mortality of about 40%. Up to 35% of pregnancies among women with 
untreated gonococcal infection result in spontaneous abortions and premature deliveries, 
and up to 10% in perinatal deaths. In the absence of prophylaxis, 30 - 50% of infants born to 
mothers with untreated gonorrhoea and up to 30% of infants born to mothers with 
untreated chlamydial infection will develop a serious eye infection (ophthalmia 
neonatorum), which can lead to blindness if not treated early. Worldwide, 1000 - 4000 
newborn babies become blind every year because of this condition. 
2.3 STIs and HIV 
The presence of untreated STIs (both those which cause ulcers or those which do not) 
increase the risk of both acquisition and transmission of HIV by a factor of up to 10. Prompt 
treatment for STIs is thus important to reduce the risk of HIV infection. Controlling STIs is 
important for preventing HIV infection, particularly in people with high-risk sexual 
behaviours.  
An estimated 34 million people were living with HIV globally at the end of 2010 including 
3.4 million children less than 15 (WHO, 2011). There was 2.7 million new HIV infections in 
2010, including 390 000 among children less than 15. Globally, the annual number of people 
newly infected with HIV continues to decline, although there is stark regional variation. In 
sub-Saharan Africa, where most of the people newly infected with HIV live, an estimated 1.9 
million  people became infected in 2010. This was 16% fewer than the estimated 2.2 million 
people newly infected with HIV in 2001 and 27% fewer than the annual number of people 
newly infected between 1996 and 1998, when the incidence of HIV in sub-Saharan Africa 
peaked overall. 
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The annual number of people dying from AIDS-related causes worldwide is steadily 
decreasing from a peak of 2.2 million in 2005 to an estimated 1.8 million  in 2010. The 
number of people dying from AIDS-related causes began to decline in 2005–2006 in sub-
Saharan Africa, South and South-East Asia and the Caribbean and has continued 
subsequently. In 2010, an estimated 250 000 children less than 15 died from AIDS-related 
causes, 20% fewer than in 2005. 
Introducing antiretroviral therapy has averted 2.5 million deaths in low- and middle-income 
countries globally since 1995. Sub-Saharan Africa accounts for the vast majority of the 
averted deaths: about 1.8 million. Providing antiretroviral prophylaxis to pregnant women 
living with HIV has prevented more than 350 000 children from acquiring HIV infection 
since 1995. Eighty-six per cent of the children who avoided infection live in sub-Saharan 
Africa, the region with the highest prevalence of HIV infection among women of 
reproductive age. 
The Political Declaration on HIV/AIDS, adopted in June 2011 by the United Nations 
General Assembly, set ambitious targets aimed at achieving universal access and the health-
related Millennium Development Goals by 2015. The WHO Global Health Sector Strategy 
on HIV/AIDS, 2011–2015, the UNAIDS 2011–2015 Strategy: Getting to Zero, and the 
UNICEF’s strategic and programmatic focus on equity will help to guide national and global 
efforts to respond to the epidemic and move from an emergency response to a long-term, 
sustainable model of delivering HIV services. 
2.4 STI syndromic approach 
The traditional method of diagnosing STIs is by laboratory tests. However, these are often 
unavailable or too expensive. Since 1990 WHO has recommended a syndromic approach for 
the diagnosis and management of STIs in patients presenting with consistently recognized 
signs and symptoms of particular STIs (WHO fact sheet 2011). The syndromic approach uses 
flowcharts to guide diagnosis and treatment is more accurate than diagnosis based on 
clinical tests alone, even in experienced hands. The syndromic approach is a scientific 
approach and offers accessible and immediate treatment that is effective. It is also more cost-
effective for some syndromes than use of laboratory tests. The pathogens causing any 
particular syndrome need to be determined locally and flow charts adapted accordingly. 
Furthermore, regular monitoring of the organisms causing each syndrome should be 
conducted on a regular basis to validate the treatment recommendations. 
3. Genital ulcers and warts 
Genital ulcers are mainly observed in the following STI’s: 
i. Syphilis caused by Treponema pallidum 
ii. Chancroid caused by Haemophilus ducreyi 
iii. Genital Herpes caused by Herpes Simplex virus 
iv. Lymphogranuloma venereum (LGV) caused by C. trachomatis 
v. Donovanosis caused by Calymmatobacterium granulomatosis 
Genital warts are mainly observed in the following STI’s 
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i. Human papilloma virus infection 
ii. Molluscum contagiosum (caused by member of poxvirus family) 
3.1 General epidemiological features 
Syphilis: is a sexually transmitted disease (STD) caused by the bacterium Treponema 
pallidum. It has often been called "the great imitator" because so many of the signs and 
symptoms are indistinguishable from those of other diseases. 
According to Centers for Disease Control and Prevention (CDC fact sheet-syphilis) 
estimates, in the United States, health officials reported over 36,000 cases of syphilis in 2006, 
including 9,756 cases of primary and secondary (P&S) syphilis. In 2006, half of all P&S 
syphilis cases were reported from 20 counties and 2 cities; and most P&S syphilis cases 
occurred in persons 20 to 39 years of age. The incidence of P&S syphilis was highest in 
women 20 to 24 years of age and in men 35 to 39 years of age. Reported cases of congenital 
syphilis in newborns increased from 2005 to 2006, with 339 new cases reported in 2005 
compared to 349 cases in 2006. 
Between 2005 and 2006, the number of reported P&S syphilis cases increased 11.8 percent. 
P&S rates have increased in males each year between 2000 and 2006 from 2.6 to 5.7 and 
among females between  2004 and 2006.  In 2006, 64% of the reported P&S syphilis cases 
were among men who have sex with men (MSM). 
The overall syphilis rate decreased for the first time in a decade, and is down 1.6 percent 
since 2009 (STD Trends US 2010). However, the rate among young black men has increased 
dramatically over the past five years (134 percent). There is a significant increase in syphilis 
among young black men who have sex with men (MSM), suggesting that new infections 
among MSM are driving the increase in young black men. There has also been a sharp 
increase in HIV infections among this population (STD Trends in the United States: 2010). 
Chancroid: Since 1987, reported cases of chancroid had declined steadily until 2001. Since 
then, the number of cases reported has fluctuated. In 2010, a total of 24 cases of chancroid 
were reported in the United States. Only nine states reported one or more cases of chancroid 
in 2010 (CDC STD surveillance 2010). Although the overall decline in reported chancroid 
cases most likely reflects a decline in the incidence of this disease, these data should be 
interpreted with caution because Haemophilus ducreyi, the causative organism of chancroid, 
is difficult to culture, and as a result, this condition may be substantially underdiagnosed. 
Genital Herpes: In US, Seroprevalence decreased from 21%  in 1988–1994 to 17.0% in 1999–
2004 and 16.2% in 2005–2008. These data also indicate that blacks had higher seroprevalence 
than whites for each survey period and age group. During 2005–2008, a survey reported a 
diagnosis of genital herpes was 18.9% in age group of 20–49 years . Although HSV-2 
seroprevalence is decreasing, most persons with HSV-2 have were not diagnosed. An increase 
in the number of visits for genital herpes, may indicate increased recognition of infection. 
Lymphogranuloma venereum (LGV): LGV is a rare disease in industrialised countries, but 
is endemic in parts of Africa, Asia, South America, and the Caribbean. Its epidemiology is 
poorly defined, since it cannot be distinguished clinically from other causes of genital 
ulceration with bubo formation—for example, chancroid, and it is   difficult to diagnose 
with confidence in the laboratory. Clinic based series of patients with genital ulcer suggest 
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that it is an uncommon cause of genital ulceration in Africa.(Htun et al., 1998; Behets et al., 
1999) Ten per cent of patients with buboes presenting to an STD clinic in Bangkok were 
found to have LGV,3 and a large epidemic of LGV has been reported recently among 
“crack” cocaine users in the Bahamas (Bauwens et al., 2002). 
Donovanosis: Even though this illness has been described for more than a century, it is 
frequently neglected because of its occurrence in unspecified geographical locations and 
with infrequent incidences. Therefore, its pathogenesis and epidemiology are not 
completely understood and require study (Veeranna and Raghu, 2003). 
This illness is more common in Afro-Americans, in individuals with a lower socio-economic 
status, and among those untrained in hygiene. It is endemic in tropical and subtropical 
climates, such as Papua New Guinea, South Africa (provinces of KwaZulu/Natal and East 
Transvaal), parts of India and Indonesia, and among the aborigines of Australia. Some cases 
have been reported in the countries of Central America and the Caribbean, Peru (where the 
first cause of chronic genital ulcers in patients with immune deficiency disorder have been 
found), Argentina, French Guiana and Brazil. This is an illness which touches almost 
exclusively adults between the ages of 20 and 40 years. There are no reports of congenital 
infections as a result of fetal infections.(O'Farrell, 2002) However, cases have been reported 
in nursing and newborn babies. Cases in children are frequently associated with contact 
with infected adults, though not necessarily because of sexual abuse. 
Human papilloma virus infection: CDC estimates in US, during 2003–2005 documented an 
overall high-risk HPV prevalence of 23%. Prevalence was 27% in STD clinics, 26% in family 
planning clinics, and 15% in primary care clinics. Prevalence by age group was 35% in 
women aged 14–19 years, 29% in those aged 20–29, 13% in those aged 30–39, 11% in those 
aged 40–49, and 6.3% in those aged 50–65 (Datta et al., 2008). 
3.2 Genital ulcers 
Infectious genital lesions are unique in a number of ways when compared with other 
infectious processes. Most are communicable and therefore are not only a clinical concern 
but also a public concern. Infectious genital lesion can harbour more than one pathogen at a 
time, making proper diagnosis and management a challenge (Dillon et al., 1997). 
Morphologic appearance of the ulcer or lesion itself can differ widely from one process to 
another and even within any single specific pathology. The unpredictable nature of lesion 
presentation can also make a purely clinical diagnosis unreliable. Inflammatory epithelial 
defects characteristic of these pathologies appear to enhance the transmission of other 
diseases, most importantly human immunodeficiency virus (HIV). Genital lesions may 
contribute substantially to the worldwide spread of this disease (Greenblatt et al., 1988). 
Genital ulcer disease involves a disruption of the skin and mucous membranes of the 
genitalia. Individuals who present with a new genital lesion and who report recent sexual 
activity, particularly activity with a new partner or someone with a suspected genital 
infection, are likely to have a sexually transmitted infection. On the other hand, certain 
clinical circumstances suggest non-sexually transmitted pathology, such as trauma, chemical 
or allergic hypersensitivity (latex allergy associated with latex condoms). A lesion that 
occurs proximate to sexual exposure (i.e., within hours to 1 or 2 days) may be too early to be 
accounted by infectious pathologies, due to variable period of incubation. 
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Host factors can be important historical determinants of genital lesion etiology. Patients 
with pre-existing psoriasis or eczema or other noninfectious dermatitides may have a genital 
lesion related to the underlying dermatologic pathology. Fixed drug eruption can be caused 
by medication such as tetracyclines or antineoplastics in a patient presenting with new 
genital lesion. In these cases, lesions may be characterized by pigmentation or superficial 
ulceration (Pandhi et al., 1984). Autoimmune diseases, such as Reiter’s syndrome, Crohn’s 
disease or Behcet’s syndrome, may be associated with genital lesions (Morgan et al., 1988; 
Keat, 1999). The important non-infectious causes of genital ulcers have to be kept in mind in 
the while keeping the differential diagnosis of gential ulcers. The clinical manifestations of 
infectious causes of genital ulcers is described below: 
3.3 Signs and symptoms 
In men lesions are found on or under the prepuce, around the coronal sulcus, on the shaft of 
the penis, the scrotum, the perianal tissue, the inner thighs or the rectum. In the female 
patients, sites of involvement are equally varied. Genital lesions can appear on the mons 
pubis, the labia, the fourchette, anywhere in the vagina, on the cervix, the inner thighs or the 
perianal tissue. As a result of orogenital sex, pathogens such as HSV and syphilis can also 
cause orolabial lesions. Lesions of chancroid can be disseminated from the genitalia and 
original site of infection to distant parts, by a process of autoinoculation, although this is not 
common (Asin, 1952).  In secondary syphilis, sometimes spirochetemia causes lesions 
widely dispersed from the genitalia that morphologically range from the classic 
papulosquamid rash of the palms and soles to the moist, raised lesions of condylomata lata 
(genitals) or mucous patches (orolabial area). Neisseria gonorrhoeae, pathogen not commonly 
associated with genital lesions, may disseminate and cause tender, necrotic pustules 
primarily on the distal extremities as part of arthritis-dermatitis syndrome (Holmes et al., 
1971).  Lesions associated with scabies infestation are common in the genital region as well 
as intertriginous areas elsewhere. Genital edema can occur after any local inflammatory 
process (Wright and Judson, 1979).  
3.4 Pain, dysesthesias and systemic symptoms 
The lesion of syphilis, lymphogranuloma venereum (LGV), scabies, and molluscum 
contagiosum are ordinarily painless. Granuloma inguinale (donovanosis), a genital ulcer 
disease seen primarily in the tropics, is caused by the bacillus Calymmatobacterium 
granulomatis. Although the lesions of this disease are often large and destructive, but it is 
painless. Most patients with exophytic genital warts are asymptomatic; a few may report 
pain or pruritus. Herpetic lesions, chancroid ulcers are typically painful. Genital lesions 
from immunologically mediated non-infectious causes may also be tender. Pain or other 
dysesthesias, including pruritis may precede the development of a recurrent disease. 
Pruritus is common only with ectoparasitic infestations such as scabies or lice. The pruritus 
associated with scabies is often described as intense and worse at night. Although pruritus 
may be experienced by individuals with herpes or syphilis, it is not characteristic of these 
conditions. Fever is occasionally seen with secondary syphilis and with primary herpes 
simplex infection (Brookes et al., 1992). Headache, fatigue, myalgias and malaise may also 
accompany these infections (Chapel, 1980). The summary of clinical features of genital ulcer 
disease is detailed in Table 1.  
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3.5 Lymphadenopathy (LAP) 
Inguinal lymphadenopathy is a nonspecific finding that is characteristic of inflammatory 
pathology almost anywhere in the groin or either lower extremity. It often accompanies 
genital infection. Although the inguinal and femoral lymph nodes drain the genital region in 
both men and women, the inner segment of the vagina and the cervix drain into deep pelvic 
and perirectal lymph nodes. If these lymph are involved in inflammatory genital pathology, 
pelvic or rectal discomfort may be the most striking symptom. 
Bilateral painless inguinal lymphadenopathy is typical in syphilis. In secondary syphilis, 
lymphadenopathy distant from the genital area is common. LAP associated with a herpetic 
genital lesion is usually bilateral and it is also tender. LGV and chancroid are characterized 
by expansive, tender lymph nodes called buboes. These may be unilateral or bilateral. A 
central area of fluctuance often develops; if left untreated. It eventually ruptures. 
Lymphadenitis is unusual in granuloma inguinale. 
3.6 Lesion morphology 
Herpes infections are characterized by vesicles that evolve into pustules and finally to 
shallow ulcers on an erythematous base. Multiple lesions are common which may erupt in 
clusters and coalesce to form a wide variety of shapes and sizes. 
Syphilitic chancres are typically solitary although they may rarely occur in pairs. They are 
round and 1 to 2 cm in diameter, with clean margins that are indurated on palpation. The 
ulcer base usually lacks exudates until and unless they are super infected with other 
bacteria. The lesions of secondary syphilis are not chancre-like. They may start anywhere as 
fine, circumferential scale. In warm, moist areas such as the buttocks and genitals, unique 
lesions of secondary syphilis known as condylomata lata develop. These are raised, moist 
nodules or plaques that are teeming with treponemes. They are highly infectious. 
Chancroid lesions are similar in size to syphilitic chancres but their edges are ragged and 
undermined. The ulcer base is necrotic with a purulent exudates. Compared with the lesions 
of syphilis, induration of chancroid lesions tends to be less prominent, accounting for the 
designation of these ulcers as “soft chancres”. Despite the obvious tissue damage, adjacent 
inflammation is absent. Usually lesions are solitary but multiple lesions may be seen. 
The lesions of granuloma inguinale start as firm subcutaneous nodules or papules that 
eventually ulcerate. Typically, this ulcerative process becomes hypertrophic and beefy and 
bleeds easily. Local tissue destruction may be extensive. Occasionally, lesions are confused 
with squamous cell carcinoma. 
Lymphogranuloma venereum (LGV) is caused by Chlamydia trachomatis serovars L1, L2 and 
L3. At its earliest stage, LGV may cause a small papule or herpes-like ulcer. This is usually 
asymptomatic and resolves before recognition. 
Clinically visible lesions of HPV are typically caused by viral types with low oncogenic 
potential (i.e. types 6 and 11). Most HPV infections are asymptomatic. Lesions may occur as 
flat or relatively inconspicuous papules to verrucous, pedunculated or large cauliflower like 
masses referred to as condylomata acuminate. 
Molluscum contagiosum causes benign, wart like lesions. The etiologic agent of this 
condition is a member of poxvirus family. 
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Lesions of scabies infestation range from papules to nodules with a surrounding crust. With 
scratching, these lesions are often modified by excoriations or lichenification. The use of 
systemic or topical antimicrobial agents before clinical evaluation have a dramatic effect on 
lesion morphology. 
3.7 Duration 
Without therapy, herpes ulcers resolve within 3 weeks in cases of primary infection and 
recurrence resolves in 5 to 10 days. In immunocompromised patients it may persist for longer 
than 3 to 4 weeks. Syphilitic chancres and condylomata lata also resolve without therapy, 
usually between 3 and 12 weeks and usually without much scarring (Larsen et al 1995). 
Without therapy, the lesions of chancroid and donovanosis are slowly destructive. Scarring is 
typical in both these conditions. Lesions caused by HPV or molluscum contagiosum may 
persist unchanged for a prolonged time or they may alternate with brief periods of resolution. 
3.8 Laboratory diagnosis 
Laboratory tests are critical to the diagnosis and proper management of genital ulcer 
disease. Direct microscopic examinations e.g. dark field microscopy or direct fluorescent 
staining can be performed on lesion exudates or a biopsy sample, which helps in making a 
diagnosis. Gram staining is not usually helpful in the evaluation of genital lesions. Lesion 
exudates is typically laden with a variety of non-pathogenic organisms common to 
genitourinary and perirectal flora. Under ideal conditions, Haemophilus ducreyi appears as a 
gram negative slender rod or coccobacillus that align in a pattern referred to as “school of 
fish”. Experienced microbiologist is required to recognize this pattern. H. ducreyi can be 
cultivated on special nutrient media using Mueller-hinton-based chocolate agar, 
supplemented with 1% IsoVitaleX and 3μg/mL vancomycin to inhibit the growth of other 
organisms (Trees and Morse, 1995). The rarity of this organism in the developed world and 
the expense and limited shelf life of the media make isolation of H. ducreyi difficult and 
uncommon. 
Light microscopy of syphilis chancre exudates is not useful. The spirochetes are extremely 
thin and do not take up standard stains. Darkfield microscopy of lesion exudates from either 
a chancre or condylomata lata can identify spirochetes. Spirochetes appear as tightly coiled, 
white organisms spirally rotating against the black background of the microscopic field. To 
perform a proper darkfield examination, ulcers must be cleaned with gauze and saline. 
Exudates from the lesion is then pressed against a glass slide. The specimen should not be 
contaminated with too much of blood. A cover slip is then applied. Rapid examination of 
the specimen is essential, because desiccation reduces the viability of organisms. In vitro T. 
pallidum can not be cultured. Other diagnostic methods include direct fluorescent antibody 
testing and silver staining methods. 
Serological testing is the most commonly used method for the diagnosis of syphilitic genital 
lesions. The process requires two steps: a screening test that detects serum antibodies to 
nontreponemal antigens (e.g., rapid plasma regain [RPR] test, Venereal Disease Research 
Laboratory [VDRL] test) and then a confirmatory test that detects serum antibody to specific 
treponemal antigens (e.g., fluorescent treponemal antibody absorbed [FTA-ABS] test, 
Treponema pallidum particle agglutination assay [TPPA]. Early after the appearance of the 
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syphilitic chancre, only the treponemal specific test may be reactive. Repeat testing with the 
nontreponemal test should be considered at some time after the ulcer has formed. In rare 
situations, the nontreponemal test may be falsely nonreactive in secondary syphilis due to 
the blocking effect of excess antibody; this is known as prozone phenomenon. Repeat testing 
should be performed on diluted serum samples. The cardiolipin antigens used in the 
detection of reaginic antibodies yield a large number of false-positive tests in many 
conditions other than syphilis, such as viral infections or autoimmune diseases (as a result of 
damage in the host's tissue). False-positive reactions have also been reported in a variety of 
acute and chronic diseases, such as mixed connective tissue disease, autoimmune disease, 
diabetes mellitus, alcoholic cirrhosis, viral infections, and pregnancy (Carlsson et al., 1991). 
VDRL has a prognostic significance also as it becomes non reactive after the successful 
treatment. Ordinarily the nontreponemal serologic test reaches its highest titer in secondary 
disease and declines with the onset of latency or with effective treatment (Larsen et al., 1995). 
Herpes simplex virus (HSV) infected genital lesions can be identified by light microscopy 
using Tzanck smear. In this process, epithelial cells are scraped from an ulcer base and stained 
with Giemsa stain. Multinucleated giant cells and intranuclear inclusions are characteristics of 
HSV infections. However, both the sensitivity and specificity of the Tzanck smear are poor 
(Solomon et al., 1986). When available, conventional cell culture provides a relatively accurate 
diagnosis. Though the culture is considered to be the gold standard, it has drawback due to 
low sensitivity and is time consuming. Fluorescent monoclonal antibodies can be used to 
detect the surface antigens in smears prepared from ulcer scrapings. Molecular techniques like 
polymerase chain reaction targeting HSV DNA polymerase, glycoprotein D encoding regions 
have been successfully used to diagnose the genital herpes. Serological test, detecting IgG 
antibodies is not useful in diagnosing acute genital lesions.  
Calymmatobacterium granulomatis, the cause of granuloma inguinale or donovanosis can be 
identified by staining scrapings of a lesion base with either Wright’s or Giemsa’s stain. 
Surface cells alone may not harbour the organism, so biopsy is often necessary. Clusters of 
blue rods, with prominent polar granules and surrounded by pink capsules are seen within 
infected epithelial cells and are known as Donovan bodies. Cultivation is difficult. 
The diagnosis of LGV is usually based on clinical criteria. Isolation by cell culture or 
polymerase chain reaction of C. Trachomatis from bubo drainage is diagnostic. The 
serological test like complement fixation test and microimmunofluorescence techniques are 
not widely available in the diagnostic laboratories outside research centres. 
The lesions of HPV are diagnosed primarily by their clinical appearance and can be assessed 
by cytologic methods (e.g., Papanicolaou smear) or biopsy. Infestation with ectoparasites 
such as Sarcoptes scabiei is demonstrated by identification of the organism, eggs or faeces 
under light microscopy. This may require the unroofing of the scabies burrow bluntly with a 
needle or scalpel. Nucleic acid detection is an increasingly common means of diagnosing 
infectious diseases. Efforts have been made to apply this technology to the diagnosis of 
some of the more common genital lesions. Nucleic acid detection can be performed with use 
of hybridization techniques, amplification techniques like PCR, TMA (transcription 
mediated amplification), ligase chain reaction (LCR). PCR test have been developed for H. 
ducreyi(Johnson et al., 1994), T. pallidum(Liu et al., 2001) and HSV(Cone et al., 1991). These 
technologies have also been combined in one “multiplex” platform to aid in the clinical 
evaluation of genital lesions. The role of such tests in current clinical practice is undefined. 
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 Syphilis Chancroid Genital herpes 
Lymphogranuloma 
Venereum 
Donovanosis 
Incubation 
period 
Avg. 21 d 
Range 3-90 d 
2-7 d 
Range 1-35 d 
2-7 d 
Avg. 10-14 d 
Range 3d – 3 wk 
Variable 
Number of 
lesions 
Usually 
single, 
occasionally 
multiple 
1-3; may be 
multiple 
Multiple; may 
coalesce 
Usually single 
Single or 
multiple 
Border 
Sharply 
demarcated 
Erythematous 
and 
undermined 
Erythematous Variable 
Rolled and 
elevated 
Base 
Red, 
smooth; 
shiny or 
crusty 
Yellow, gray; 
rough 
Red, smooth Variable 
Red, rough, 
may be 
friable, beefy 
granulations 
Induration Firm Rare, soft None None Firm 
Pain 
Painless; 
pain may 
occur with 
secondary 
infection 
Common Common Variable Rare 
Lymphnodes 
Unilateral to 
bilateral; 
nontender, 
firm 
Usually 
unilateral; 
may 
suppurate 
Usually 
bilateral;  
firm and 
tender 
Unilateral or 
bilateral; firm 
tender, later 
indolent, may 
suppurate, groove 
sign present 
Pseudo-
adenopathy, 
inguinal 
swelling 
Constitutional 
symptoms 
Rare Rare 
Common in 
primary 
disease 
Frequent Rare 
Table 1. Summary of clinical features of genital ulcer disease(Wilson and Sande). 
3.9 Complications 
All genital ulcers are prone to secondary bacterial infections with a variety of genital 
bacteria. Additionally, edema of the foreskin in uncircumcised men may produce 
phimosis. Without treatment, chancres of primary syphilis and lesions of genital herpes 
heal spontaneously. Patients with syphilis progress into the secondary stage, whereas 
those with genital herpes may later experience recurrence of their lesions. The ulcers of 
chancroid and LGV continue to grow slowly by local extension and can produce further 
tissue and organ damage. LGV may further lead to perianal abscesses and rectovaginal, 
rectovesical and anal fistulas and strictures. Lymphatic obstruction and edema may occur. 
Rectal LGV is associated with an increased incidence of rectal cancer. Complications of 
donovanosis scarring include urethral, vaginal and anal strictures and lymphedema of the 
external genitalia. 
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3.10 Treatment 
Syphilis: Penicillin remains the treatment of choice for any stage of syphilis. For the 
penicillin allergic patient, doxycycline or tetracycline is treatment of choice. 
Chancroid: A single dose of intramuscular ceftriaxone or oral azithromycin or 7 days of 
erythromycin are recommended first-line treatments. Alternative therapies include 
amoxicillin/clavulanic acid or ciprofloxacin. Fluctuant adenopathy may require needle 
aspiration or drainage. 
Genital Herpes: Uncomplicated genital herpes heals spontaneously. Treatment is available 
to decrease viral shedding and shorten the duration of illness. For first episode genital 
herpes, oral acyclovir, valacyclovir or famciclovir is recommended for 10 days. For recurrent 
disease, any one of these regimens can be given for an additional 5 days. Suppressive 
therapy is recommended for patients with severe and frequent recurrent episodes of genital 
herpes. 
4. Urethritis 
Urethritis is the most common sexually transmitted disease (STD) syndrome recognized in 
men and is frequently seen in women with coinciding cervicitis. Cases can be of two types, 
gonococcal urethritis and nongonococcal urethritis (NGU), based on the presence or absence 
of Neiserria gonorrhoeae. The two forms are not mutually exclusive. Coinfection with Neiserria 
gonorrhoeae and Chlamydia trachomatis or Ureaplasma urealyticum occurs in 15-25% of 
heterosexual men with urethritis. Other agents which can cause NGU are Trichomonas 
vaginalis, Herpes simplex virus, Mycoplasma genitalium, Candida spp. NGU that occurs soon 
after curative therapy for gonorrhoea is called as postgonococcal urethritis (PGU). 
The Centers for Disease Control and prevention estimates that NGU is 2.5-fold more 
prevalent than gonococcal urethritis in the United States and much of the developed world. 
However, gonococcal urethritis accounts for upto 80% of acute urethritis cases in certain 
underdeveloped regions of the world. Among people of higher socioeconomic status and 
college students, NGU is more common. In urban STD clinics, gonococcal urethritis is more 
common.  
4.1 Gonococcal urethritis 
N. gonorrhoeae is a gram-negative intracellular coccus that characteristically grows in pairs 
(diplococci). Over the last 25 years, the prevalence of penicillin and tetracycline-resistant 
gonococci has been increasing worldwide, requiring alternative treatment strategies. N 
gonorrhoeae may not be limited to uethritis only but coinfection of the cervix, rectum or 
pharynx may also be there. Some patients may also present with disseminated infection. 
4.2 Non-Gonococcal Urethritis (NGU) 
Nongonoccocal urethritis (NGU), which is suspected when examination findings and 
microscopy indicate inflammation and Gram-negative intracellular diplococci (GNID) can 
not be observed in stained smears and/ or culture. C. trachomatis is the most common 
etiological agent leading to NGU, in 15%–40% of cases; however, prevalence varies by age 
www.intechopen.com
 
Sexually Transmitted Infections: An Overview 
 
15 
group, with a lower burden of disease occurring among older men (Bradshaw et al., 2006). 
Complications of NGU among males infected with C. trachomatisinclude epididymitis and 
Reiter’s syndrome. Documentation of chlamydial infection is essential because of the need 
for partner referral for evaluation and treatment. In most cases of nonchlamydial NGU, no 
pathogen can be detected. M. genitalium, which appears to be sexually transmitted, is 
associated with both symptoms of urethritis and urethral inflammation and accounts for 
15%–25% of NGU cases in the United States (Taylor-Robinson et al., 2004; Manhart et al., 
2007). T. vaginalis, HSV, and adenovirus also can cause NGU, but data supporting other 
Mycoplasma species and Ureaplasma as etiologic agents are inconsistent. Diagnostic and 
treatment procedures for these organisms are reserved for situations in which these 
infections are suspected (e.g., contact with trichomoniasis, genital lesions, or severe dysuria 
and meatitis, which might suggest genital herpes) or when NGU is not responsive to 
therapy. Enteric bacteria have been identified as an uncommon cause of NGU and might be 
associated with insertive anal intercourse.  
4.3 Diagnosis 
Clinicians should attempt to obtain objective evidence of urethral inflammation. However, if 
clinic-based diagnostic tools (e.g., Gram-stain microscopy) are not available, patients should 
be treated with drug regimens effective against both gonorrhea and chlamydia. The 
clinically distinguishing features of gonococcal and nongonococcal urethritis are detailed in 
Table 2. Urethritis can be documented on the basis of any of the following signs and/ or 
laboratory tests: 
 Mucopurulent or purulent discharge on examination. 
 Gram stain of urethral secretions demonstrating ≥5 WBC per oil immersion field. The 
Gram stain is the preferred rapid diagnostic test for evaluating urethritis and is highly 
sensitive and specific for documenting both urethritis and the presence or absence of 
gonococcal infection. Gonococcal infection is established by documenting the presence 
of WBC containing gram-negative intracellular diplococci (GNID). 
 Positive leukocyte esterase test on first-void urine or microscopic examination of first-
void urine sediment demonstrating ≥10 WBC per high-power field. 
If the urethral Gram stain is negative for gonococci, a culture should be done. N. gonorrhoeae 
is a  fastidious organism requiring a selective growth medium in a carbon dioxide rich 
environment. Selective growth media include Thayer-Martin, Martin Lewis and New York 
city media. Nonculture or rapid diagnostic tests for gonococcal infection include Gonozyme, 
the Gen-Probe Pace 2 and the ligase chain reaction (LCR). Gonozyme is an enzyme 
immunoassay that can detect gonococcal antigens within urethra, cervix and urine. The gen-
probe pace 2 use nonisotopic probes to detect ribosomal RNA. LCR utilizes a DNA 
amplification technique to detect trace amounts of organism-specific nucleic acid sequences 
from uretheral and endo-cervical swab specimens and urine samples. 
4.4 Detection of C. trachomatis 
Cell culture is considered to be the gold standard for chlamydial testing (Gottlieb et al., 
2010). It has a sensitivity of 75-80% and a specificity approaching 100%. The addition of an 
www.intechopen.com
 
Sexually Transmitted Infections 
 
16
enzyme immunoassay to culture increases the sensitivity to 95%. Cultures are expensive 
and may require 3-7 days for results. Nonculture rapid diagnostic tests, including direct 
fluorescence antibody (DFA) test, enzyme linked immunoassay test (EIA) and DNA probe 
tests, provide a more prompt diagnosis than culture with roughly an equivalent 
specificity (Su et al., 2011) The sensitivity is 70-90%. The Gen-Probe Pace 2 and LCR 
assays detect rRNA and DNA sequences, respectively of both N. gonorrhoeae and C. 
trachomatis. The sensitivity is higher than that of cell cultures without compromise in 
specificity. 
If none of these criteria are present, testing for N. gonorrhoeae and C. trachomatis using nucleic 
acid amplification tests (NAATs) might identify additional infections. If the results 
demonstrate infection with either of these pathogens, the appropriate treatment should be 
given and sex partners referred for evaluation and treatment. If none of these criteria are 
present, empiric treatment of symptomatic males is recommended only for men at high risk 
for infection who are unlikely to return for a follow-up evaluation. Such patients should be 
treated with drug regimens effective against Gonorrhea and Chlamydia. Partners of patients 
treated empirically should be evaluated and treated, if indicated. 
4.5 Detection of other pathogens 
U. urealyticum is identified by culture. Because U. urealyticum can be isolated in men without 
urethritis, a positive culture for U. urealyticum may not necessarily indicate the cause of 
urethritis. The rapid and less expensive method for the diagnosis of trichomoniasis is the 
direct microscopic wet mount examination of vaginal or urethral discharge. The accuracy of 
the exam is based on identifying motile protozoa with characteristic morphology. The wet 
mount exam is routinely used to evaluate women for vaginal trichomoniasis (50-70% 
sensitive) but is less sensitive with urethral discharge from infected men. The gold standard 
for diagnosing of trichomoniasis is isolating the protozoa in culture. 
4.6 Treatment 
Gonococcal Urethritis: Uncomplicated urethritis can be treated with Ceftriaxone 250 mg 
intramuscular single dose, or Cefixime 400 mg PO single dose. In 1976, penicillin-resistant 
gonococci were identified and found to have acquired plasmids encoding for the production 
of beta-lactamase. Approximately 15% of all gonococci in the United States are now 
penicillin resistant. In some urban areas, the incidence is as high as 60-75%. In 1985, 
tetracycline-resistant gonococci were identified and also found to have plasmid encoded 
resistance (Johnson et al., 1988). Tetracycline resistant gonococci are responsible for upto 
15% of gonococcal infections along the eastern coast of the United States. N. gonorrhoeae with 
chromosomal mutations conferring penicillin and tetracycline resistance has also been 
identified. Because of the increasing frequency of penicillin and tetracycline resistant 
gonococci, the penicillins and tetracyclines are no longer recommended. Quinolone resistant 
gonococci have also been identified. 
Intramuscular ceftriaxone cures nearly 100% of genital infections and is effective for the 
treatment of gonococcal infection at all sites. Ceftriaxone is also active against incubating 
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syphilis. Oral cefixime is nearly as active against N. gonorrhoeae and is less expensive. For the 
beta-lactam-allergic patients, oral ciprofloxacin or ofloxacin is highly effective. 
Many patients who experience symptomatic relief after a single dose treatment for 
gonococcal urethritis develop a prompt recurrence or persistence of milder symptoms. This 
syndrome is called postgonococcal urethritis (PGU) and is the result of dual infection of the 
urethra with N gonorrhoeae and organism of NGU (Gaydos et al., 2009). N gonorrhoeae is 
eradicated by a single dose of the aforementioned cephalosporins and quinolones but the 
organisms responsible for NGU are often spared. PGU should be suspected if signs, 
symptoms or laboratory evidence of urethritis is found 4-7 days after a single-dose 
treatment for gonococcal urethritis. Unless chlamydial infection has been specifically ruled 
out through testing, all patients treated for gonococcal infections should also be treated for 
chlamydial infections. 
Treatment of NGU: Azithromycin and doxycycline are highly effective for chlamydial 
urethritis; however, infections with M. genitalium respond better to azithromycin. Single-
dose regimens have the advantage of improved compliance and directly observed 
treatment. To maximize compliance with recommended therapies, medications should be 
dispensed on-site in the clinic, and the first dose should be directly observed. To minimize 
transmission, men treated for NGU should be instructed to abstain from sexual intercourse 
for 7 days after single-dose therapy or until completion of a 7-day regimen, provided their 
symptoms have resolved. To minimize the risk for reinfection, men should be instructed to 
abstain from sexual intercourse until all of their sex partners are treated. 
Tetracycline/doxycyline resistant U urealyticum exist and is the basis of for treating patients 
with erythromycin who fail standard therapy. Treatment of urethritis due to Trichomonas is 
usually effective with a single oral dose of metronidazole. 
Persons who have been diagnosed with a new STD should testing for other infections, 
including syphilis and HIV. 
4.7 Follow-up 
Patients should be instructed to return for evaluation if symptoms persist or recur after 
completion of therapy. Symptoms alone, without documentation of signs or laboratory 
evidence of urethral inflammation, are not a sufficient basis for retreatment. Providers 
should be alert to the possibility of chronic prostatitis/chronic pelvic pain syndrome in male 
patients experiencing persistent pain (perineal, penile, or pelvic), discomfort, irritative 
voiding symptoms, pain during or after ejaculation, or new-onset premature ejaculation 
lasting for >3 months. 
Unless a patient’s symptoms persist or therapeutic noncompliance or reinfection is 
suspected by the provider, a test-of-cure (i.e., repeat testing 3–4 weeks after completing 
therapy) is not recommended for persons with documented chlamydia or gonococcal 
infections who have received treatment with recommended or alterative regimens. 
However, because men with documented chlamydial or gonococcal infections have a high 
rate of reinfection within 6 months after treatment, repeat testing of all men diagnosed with 
chlamydia or gonorrhea is recommended 3–6 months after treatment, regardless of whether 
patients believe that their sex partners were treated. 
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Clinical finding Gonorrhea NGU 
Onset of symptoms 
Classically abrupt 
75% men develop 
symptoms within 4 days; 
80-90% men develop 
symptoms within 2 
weeks 
Less acute onset 
Approx. 50% men 
develop symptoms 
within 4 days 
Frankly purulent urethral discharge 75% 11-33% 
Mucopurulent discharge 25% 50% 
Completely clear discharge 4% 10-50% 
Dysuria 73-88% 53-75% 
Table 2. Summary of clinical features of gonococcal and nongonococcal urethritis 
(Wilson and Sande). 
5. Cervicitis 
The microbial agents leading to cervicitis are: 
i. N. gonorrhoeae 
ii. C. trachomatis 
iii. T. vaginalis 
iv. Herpes simplex virus (HSV) 
v. Human papilloma virus (HPV) 
Two major diagnostic signs characterize cervicitis:  
1. A purulent or mucopurulent endocervical exudate visible in the endocervical canal or 
on an endocervical swab specimen (commonly referred to as mucopurulent cervicitis or 
cervicitis) 
2. Sustained endocervical bleeding easily induced by gentle passage of a cotton swab 
through the cervical os. Either or both signs might be present. Cervicitis frequently is 
asymptomatic, but some women complain of an abnormal vaginal discharge and 
intermenstrual vaginal bleeding (e.g., after sexual intercourse). A finding of leukorrhea 
(>10 WBC per high-power field on microscopic examination of vaginal fluid) has been 
associated with chlamydial and gonococcal infection of the cervix. In the absence of 
inflammatory vaginitis, leukorrhea might be a sensitive indicator of cervical 
inflammation with a high negative predictive value. Although some specialists consider 
an increased number of polymorphonuclear leukocytes on endocervical Gram stain as 
being useful in the diagnosis of cervicitis, this criterion has not been standardized. In 
addition, it has a low positive-predictive value (PPV) for infection with C. trachomatis 
and N. gonorrhoeae and is not available in most clinical settings. Finally, although the 
presence of GNID on Gram stain of endocervical fluid is specific for the diagnosis of 
gonococcal cervical infection, it is not a sensitive indicator, because it is observed in 
only 50% of women with this infection. 
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5.1 Etiology 
Mainly C. trachomatis or N. gonorrhoeae are the main etiological agents in patients suspected of 
cervicitis.(Hosenfeld et al., 2009) Cervicitis can also be observed in trichomoniasis and genital 
herpes (especially primary HSV-2 infection). However, in most cases of cervicitis, no 
organism is isolated, especially in women at relatively low risk for recent acquisition of 
these STDs (e.g., women aged >30 years). Limited data indicate that infection with M. 
genitalium and bacterial vaginosis (BV) and frequent douching might cause cervicitis. For 
reasons that are unclear, cervicitis can persist despite repeated courses of antimicrobial 
therapy, because most persistent cases of cervicitis are not caused by relapse or reinfection 
with C. trachomatis or N. gonorrhoeae. Other factors (e.g., persistent abnormality of vaginal 
flora, douching, or idiopathic inflammation in the zone of ectopy) might be involved. 
5.2 Diagnosis 
Cervicitis might be a sign of upper-genital–tract infection (endometritis), and thus women 
who seek medical treatment for a new episode of cervicitis should be assessed for signs of 
pelvic inflammatory disease (PID) and should be tested for C. trachomatis and for N. 
gonorrhoeae with the sensitive and specific tests available. Women with cervicitis also should 
be evaluated for the presence of Add Bacterial Vaginosis (BV) and trichomoniasis, for 
indicating specific treatment. The sensitivity of microscopy to detect T. vaginalis is relatively 
low (approximately 50%), symptomatic women with cervicitis and negative microscopy for 
trichomonads should be subjected to sensitive tests (i.e., culture or other FDA-cleared 
method). Although HSV-2 infection has been associated with cervicitis, the utility of specific 
testing (i.e., culture or serologic testing) for HSV-2 in this setting is unknown. Standardized 
diagnostic tests for M. genitalium are not commercially available. 
Nucleic acid amplification technique (NAAT) should be used for diagnosing C. trachomatis 
and N. gonorrhoeae in women with cervicitis; this testing can be performed on either vaginal, 
cervical, or urine samples. A finding of >10 WBC in vaginal fluid, in the absence of 
trichomoniasis, might indicate endocervical inflammation caused specifically by C. 
trachomatis or N. gonorrhoeae. 
5.3 Treatment 
Several factors should affect the decision to provide presumptive therapy for cervicitis or 
to await the results of diagnostic tests. Treatment with antibiotics for C. trachomatis should 
be provided for those women at increased risk for this common STD (e.g., those aged ≤25 
years, those with new or multiple sex partners, and those who engage in unprotected sex), 
especially if follow-up cannot be ensured and if a relatively insensitive diagnostic test is 
used in place of NAAT. Concurrent therapy for N. gonorrhoeae is indicated if the 
prevalence of this infection is >5% (those in younger age groups and those living in 
certain facilities). 
Trichomoniasis and BV, if detected should also be treated. For women in whom any 
component of (or all) presumptive therapy is deferred, the results of sensitive tests for C. 
trachomatis and N. gonorrhoeae (e.g., NAATs) should determine the need for treatment 
subsequent to the initial evaluation. 
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5.4 Recommended regimens for presumptive treatment 
Azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice a day for 7 
days 
Concurrent treatment for gonococcal infection should be considered, if prevalence of 
gonorrhea is high in the patient population under assessment. 
5.5 Recurrent and persistent cervicitis 
Women with persistent cervicitis should be reevaluated for possible reexposure to an STD. If 
relapse and/or reinfection with a specific STD has been excluded, BV is not present, and sex 
partners have been evaluated and treated, management options for persistent cervicitis are 
undefined; in addition, the utility of repeated or prolonged administration of antibiotic 
therapy for persistent symptomatic cervicitis remains unknown. Women who receive such 
therapy should be followed up post-treatment so that a determination can be made regarding 
whether cervicitis has resolved. Research is needed on the etiology of persistent cervicitis 
including the potential role of M. genitalium. In women with persistent symptoms that are 
clearly attributable to cervicitis, referral to a gynecologic specialist can be considered. 
5.6 Follow up 
Follow-up should be conducted as recommended for the infections for which a woman is 
treated. If symptoms persist, women should be instructed to return for re-evaluation 
because women with documented chlamydial or gonococcal infections have a high rate of 
reinfection within 6 months after treatment. Therefore, repeat testing of all women for 
Chlamydia and/ or Gonococcus is recommended 3-6 months after treatment, regardless of 
whether their sex partners were treated. 
5.7 Management of sex partners 
Management of sex partners of women treated for cervicitis should be appropriate for the 
identified or suspected STD. Partners should be notified and examined if Chlamydia, 
Gonococcus, or T. vaginalis was identified or suspected in the index patient; these partners 
should then be treated for the STDs for which the index patient received treatment. To 
avoid reinfection, patients and their sex partners should abstain from sexual intercourse 
until therapy is completed (i.e., 7 days after a single-dose regimen or after completion of a 
7-day regimen). Expedited partner treatment and patient referral are alternative 
approaches to treating male partners of women that have Chlamydia or gonococcal 
infections. 
6. Sexually transmitted infections characterized by vaginal discharge 
Most women will have a vaginal infection, characterized by discharge, itching, or odor, 
during their lifetime. Obtaining a medical history alone has been shown to be insufficient for 
accurate diagnosis of vaginitis and can lead to the inappropriate administration of 
medication. Therefore, a careful history, examination, and laboratory testing to determine 
the etiology of vaginal complaints are warranted. Information on sexual behaviors and 
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practices, gender of sex partners, menstrual history, vaginal hygiene practices (such as 
douching), and other medications should be elicited. The three diseases most frequently 
associated with vaginal discharge are bacterial vaginosis (BV caused by the replacement of 
the vaginal flora by an overgrowth of anaerobic bacteria including Prevotella sp., Mobiluncus 
sp., G. vaginalis, Ureaplasma, Mycoplasma, and numerous fastidious or uncultivated 
anaerobes), trichomoniasis (caused by T. vaginalis), and candidiasis (usually caused by 
Candida albicans). The summary of clinical features of vaginitis is depicted in Table 3. 
Cervicitis also can sometimes cause a vaginal discharge. Although vulvovaginal 
candidiasis (VVC) usually is not transmitted sexually, it is included in this chapter 
because it is frequently diagnosed in women who have vaginal complaints or who are 
being evaluated for STDs. 
Various diagnostic methods are available to identify the etiology of an abnormal vaginal 
discharge (Khan et al., 2009). Clinical laboratory testing can identify the cause of vaginitis in 
most women. The cause of vaginal symptoms might be determined by pH, a potassium 
hydroxide (KOH) test, and microscopic examination of fresh samples of the discharge on 
bed side examination. The pH of the vaginal secretions can be determined by narrow-range 
pH paper; an elevated pH (i.e., >4.5) is common with BV or trichomoniasis. Because pH 
testing is not highly specific, discharge should be further examined microscopically by first 
diluting one sample in one to two drops of 0.9% normal saline solution on one slide and a 
second sample in 10% KOH solution. Cover slips are then placed on the slides, and they are 
examined under a microscope at low and high power. Samples that emit an amine odor 
immediately upon application of KOH suggest BV or trichomoniasis infection. 
The saline-solution specimen might yield motile T. vaginalis, or clue cells (i.e., epithelial cells 
with borders obscured by small bacteria), which are characteristic of BV, whereas the 
presence of WBCs without evidence of trichomonads or yeast is suggestive of cervicitis. The 
KOH specimen typically is used to identify the yeast or pseudohyphae of Candida species. 
However, the absence of trichomonads or pseudohyphae in KOH samples does not rule out 
these infections, because the sensitivity of microscopy is approximately 50% compared with 
NAAT or culture. 
In settings where pH paper, KOH, and microscopy are not available, alternative 
commercially available point-of-care tests or clinical laboratory testing can be used to 
diagnose vaginitis. The presence of objective signs of vulvar inflammation in the absence of 
vaginal pathogens after laboratory testing, along with a minimal amount of discharge, 
suggests the possibility of mechanical, chemical, allergic, or other noninfectious irritation of 
the vulva. 
6.1 Bacterial Vaginosis (BV) 
BV is a polymicrobial clinical syndrome resulting from replacement of the normal hydrogen 
peroxide producing Lactobacillus sp. in the vagina with high concentrations of anaerobic 
bacteria (e.g.,Prevotella sp. and Mobiluncus sp.), G. vaginalis, Ureaplasma, Mycoplasma, and 
numerous fastidious or uncultivated anaerobes (Livengood, 2009). Some women experience 
transient vaginal microbial changes, whereas others experience them for a longer intervals 
of time. Among women attending hospital for routine checkup, BV is the most prevalent 
cause of vaginal discharge or malodour. BV is associated with having multiple male or 
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female partners, a new sex partner, douching, lack of condom use, and lack of vaginal 
lactobacilli; women who have never been sexually active can also be affected. The cause of 
the microbial alteration that characterizes BV is not fully understood, nor is whether BV 
results from acquisition of a sexually transmitted pathogen. Nonetheless, women with BV 
are at increased risk for the acquisition of some STDs (e.g., HIV, N. gonorrhoeae, C. 
trachomatis, and HSV), complications after gynecologic surgery, complications of pregnancy, 
and recurrence of BV. Treatment of male sex partners has not been beneficial in preventing 
the recurrence of BV. 
6.2 Diagnosis 
BV can be diagnosed by the use of clinical criteria (i.e., Amsel’s Diagnostic Criteria) or Gram 
stain. A Gram stain, considered the gold standard laboratory method for diagnosing BV, is 
used to determine the relative concentration of lactobacilli (i.e., long Gram-positive rods), 
Gram-negative and Gram-variable rods and cocci (i.e., G. vaginalis, Prevotella, Porphyromonas, 
and peptostreptococci), and curved Gram-negative rods (i.e., Mobiluncus) characteristic of BV 
(Khan et al., 2009). If a Gram stain is not available, clinical criteria can be used and require 
three of the following symptoms or signs: 
 homogeneous, thin, white discharge that smoothly coats the vaginal walls; 
 presence of clue cells on microscopic examination; 
 pH of vaginal fluid >4.5;  
 a fishy odor of vaginal discharge before or after addition of 10% KOH (i.e., the whiff 
test). 
Detection of three of these criteria has been correlated with results by Gram stain. Other 
tests, including a DNA probe-based test for high concentrations of G. vaginalis (Affirm VP 
III, Becton Dickinson, Sparks, Maryland), a proline-aminopeptidase test card (Pip Activity 
TestCard, Quidel, San Diego, California), and the OSOM BVBlue test have acceptable 
performance characteristics compared with Gram stain. Although a card test is available for 
the detection of elevated pH and trimethylamine, it has low sensitivity and specificity and 
therefore is not recommended. PCR  has been used in research settings for the detection of a 
variety of organisms associated with BV, but evaluation of its clinical utility is uncertain. 
Detection of one organism or group of organisms might be predictive of BV by Gram stain. 
However, additional evaluations are needed to confirm these associations. Culture of G. 
vaginalis is not recommended as a diagnostic tool because it is not specific. Cervical Pap tests 
have no clinical utility for the diagnosis of BV because of their low sensitivity. 
6.3 Treatment 
Treatment is recommended for women with symptoms. The established benefits of therapy 
in nonpregnant women are to relieve vaginal symptoms and signs of infection. Other 
potential benefits to treatment include reduction in the risk for acquiring C. trachomatis or N. 
gonorrhoeae, HIV, and other viral STDs. 
Recommended drugs: Metronidazole 500 mg orally twice a day for 7 days, Metronidazole 
gel 0.75%, one full applicator (5 g) intravaginally, once a day for 5 days; Clindamycin cream 
2%, one full applicator (5 g) intravaginally at bedtime for 7 days. 
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7. Trichomoniasis 
Trichomoniasis is caused by the protozoan T. vaginalis.(Nanda et al., 2006) Few men who are 
infected with T. Vaginalis might not have symptoms; others have NGU. Few women have 
symptoms characterized by a diffuse, malodorous, yellow-green vaginal discharge with 
vulvar irritation. However, many women have minimal or no symptoms. Because of the 
high prevalence of trichomoniasis in clinical and nonclinical settings, testing for T. vaginalis 
should be performed in women seeking care for vaginal discharge. Screening for T. vaginalis 
in women can be considered in those at high risk for infection (i.e., women who have new or 
multiple partners, have a history of STDs, indulge in sexual activity for payment, and use 
injection drugs). 
7.1 Treatment 
Metronidazole 2 g orally in a single dose or Tinidazole 2 g orally in a single dose or 
Metronidazole 500 mg orally twice a day for 7 days. 
8. Vulvovaginal Candidiasis (VVC) 
VVC is usually caused by C.albicans, but occasionally is caused by other Candida sp. or 
yeasts. Typical symptoms of VVC include pruritus, vaginal soreness, dyspareunia, 
external dysuria, and abnormal vaginal discharge. However, none of these symptoms is 
specific for VVC. An estimated 75% of women will have at least one episode of VVC, and 
40%–45% will have two or more episodes within their lifetime. On the basis of clinical 
presentation, microbiology, host factors, and response to therapy, VVC can be classified as 
either uncomplicated or complicated. Approximately 10%–20% of women will have 
complicated VVC that necessitates diagnostic and therapeutic considerations. 
8.1 Uncomplicated VVC 
Diagnostic Considerations: A diagnosis of Candida vaginitis is suggested clinically by the 
presence of external dysuria and vulvar pruritus, pain, swelling, and redness. Signs include 
vulvar edema, fissures, excoriations, or thick, curdy vaginal discharge. The diagnosis can be 
made in a woman who has signs and symptoms of vaginitis when either 1) a wet 
preparation (saline, 10% KOH) or Gram stain of vaginal discharge demonstrates yeasts, 
hyphae, or pseudohyphae or 2) a culture or other test yields a yeast species. Candida 
vaginitis is associated with a normal vaginal pH (<4.5), and therefore, pH testing is not a 
useful diagnostic tool. Use of 10% KOH in wet preparations improves the visualization of 
yeast and mycelia by disrupting cellular material that might obscure the yeast or 
pseudohyphae. Examination of a wet mount with KOH preparation should be performed 
for all women with symptoms or signs of VVC, and women with a positive result should 
receive treatment. For women with negative wet mounts who are symptomatic, vaginal 
cultures for Candida should be considered. If the wet mount is negative and Candida 
cultures cannot be done, empiric treatment can be considered for symptomatic women 
with any sign of VVC on examination. Identifying Candida by culture in the absence of 
symptoms or signs is not an indication for treatment, because approximately 10%–20% of 
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women harbor Candida sp. and other yeasts in the vagina. VVC can occur concomitantly 
with STDs. Most healthy women with uncomplicated VVC have no identifiable 
precipitating factors. 
8.2 Treatment 
Short-course topical formulations e.g. Butoconazole 2% cream, Clotrimazole 2% cream, 
Miconazole 2% cream (i.e., single dose and regimens of 1–3 days) effectively treat 
uncomplicated VVC. The topically applied azole drugs are more effective than nystatin. 
Treatment with azoles results in relief of symptoms and negative cultures in 80%–90% of 
patients who complete therapy. 
8.3 Complicated VVC 
Recurrent Vulvovaginal Candidiasis (RVVC) 
RVVC, usually defined as four or more episodes of symptomatic VVC in 1 year, affects a 
small percentage of women (<5%).(STD guidelines 2010) The pathogenesis of RVVC is 
poorly understood, and most women with RVVC have no apparent predisposing or 
underlying conditions. Vaginal cultures should be obtained from patients with RVVC to 
confirm the clinical diagnosis and to identify unusual species (including nonalbicans 
species), particularly Candida glabrata. Although C. glabrata and other nonalbicans Candidia 
species are observed in 10%–20% of patients with RVVC conventional antimycotic therapies 
are not as effective against these species as they are against C. albicans. 
8.4 Treatment 
Each individual episode of RVVC caused by C. albicans responds well to short-duration oral 
or topical azole therapy. However, to maintain clinical and mycologic control, some 
specialists recommend a longer duration of initial therapy (e.g., 7–14 days of topical therapy 
or a 100-mg, 150-mg, or 200-mg oral dose of fluconazole every third day for a total of 3 
doses [day 1, 4, and 7]) to attempt mycologic remission before initiating a maintenance 
antifungal regimen. 
Maintenance Regimens: Oral fluconazole (i.e., 100-mg, 150-mg, or 200-mg dose) weekly for 
6 months is the first line of treatment. If this regimen is not feasible, topical treatments used 
intermittently as a maintenance regimen can be considered. Suppressive maintenance 
antifungal therapies are effective in reducing RVVC. However, 30%–50% of women will 
have recurrent disease after maintenance therapy is discontinued. Routine treatment of sex 
partners is controversial. C. albicans azole resistance is rare in vaginal isolates, and 
susceptibility testing is usually not warranted for individual treatment guidance. 
Non albicans VVC 
The optimal treatment of nonalbicans VVC remains unknown. Options include longer 
duration of therapy (7–14 days) with a nonfluconazole azole drug (oral or topical) as first-
line therapy. If recurrence occurs, 600 mg of boric acid in a gelatin capsule is recommended, 
administered vaginally once daily for 2 weeks. This regimen has clinical and mycologic 
eradication rates of approximately 70%. If symptoms recur, referral to a specialist is advised. 
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 Normal 
Vulvovaginal 
candidiasis 
Trichomoniasis 
Bacterial 
Vaginosis 
Symptoms None Pruritis 
Soreness 
Dyspareunia 
Soreness 
Dyspareunia 
Often 
asymptomatic 
Often 
asymptomatic 
Occasional 
abdominal pain 
Discharge 
Amount 
Color 
Consistency 
Variable 
Clear/white 
Nonhomogenous 
floccular 
Scant/moderate 
White 
Clumped,  
adherent 
Profuse 
Green-yellow 
Homogenous, 
frothy 
Moderate 
White/gray 
Homogenous 
adherent 
Vaginal fluid 
pH 
4.0-4.5 4.0-4.5 5.0-6.0 >4.5 
Amine test 
(Fish odour) 
None None Usually positive Positive 
Microscopy 
Saline 
 
 
 
 
 
10% KOH 
 
PMN:EC ratio <1 
Lactobacilli 
predominate 
 
 
 
Negative 
 
PMN:EC ratio <1 
Pseudohyphae (~40%) 
 
 
 
 
Pseudohyphae (~70%) 
 
PMN:EC ratio >1 
Motile 
trichomonads 
PMNs 
predominate 
 
Negative 
 
PMN:EC ratio <1 
Clue cells 
Coccobacilli 
 
 
 
Negative 
Table 3. Summary of clinical features of vaginitis (Wilson and Sande). 
9. Pelvic Inflammatory Disease (PID) 
PID comprises a spectrum of inflammatory disorders of the upper female genital tract, 
including any combination of endometritis, salpingitis, tubo-ovarian abscess, and pelvic 
peritonitis. Sexually transmitted organisms, especially N. gonorrhoeae and C. trachomatis, 
are implicated in many cases; however, microorganisms that comprise the vaginal flora 
e.g., anaerobes, G. vaginalis, Haemophilus influenzae, enteric Gram-negative rods, and 
Streptococcus agalactiae,  also have been associated with PID. In addition, M. hominis, U. 
urealyticum, and M. genitalium might be associated with some cases of PID. All women 
who have acute PID should be tested for N. gonorrhoeae and C. trachomatis and should be 
screened for HIV infection. Symptoms of PID include abnormal cervical or vaginal 
discharge, abdominal pain and fever. On examination there may be cervical motion and 
adnexal and lower abdominal tenderness. It is important to diagnose and treat PID as 
early as possible. For patients requiring hospitalization, intravenous cefoxitin or cefotetan 
plus doxycyline (i/v or oral) can be given. Alternatively clindamycin plus gentamicin can 
be given followed by oral doxycycline. Outpatient treatments include oral ofloxacin plus 
metronidazole or ceftriaxone (or cefixitin and oral probenecid) plus oral doxycycline. 
Duration of intravenous treatment is dependent on the severity of the clinical presentation 
(Romanowski, 1993). 
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10. Epididymitis 
In men under age 35, the most common pathogens are N. gonorrhoeae and C. 
trachomatis(Trojian et al., 2009). Homosexual men may have enteric pathogens from rectal 
intercourse. Unilateral testicular pain and tenderness are common. There is usually palpable 
swelling of the epididymis. The evaluation and diagnostic tests are the same as those for 
urethritis. Treatment includes ceftriaxone plus doxycyline or ofloxacin (Berger, 1991). 
11. Proctitis 
Proctitis acquired through receptive anal intercourse can be caused by N. gonorrhoeae, C. 
trachomatis (including LGV serovars), T. pallidum (syphilis) and HSV. Treatment includes 
ceftriaxone plus doxycyline. 
12. Prevention 
The most effective means to avoid becoming infected with or transmitting a sexually 
transmitted infection is to have sexual intercourse only within a long-term, mutually 
monogamous relationship with an uninfected partner and to abstain from sexual intercourse 
(i.e., oral, vaginal, or anal sex) with multiple partners. Male latex condoms, when used 
consistently and correctly, are highly effective in reducing the transmission of HIV and 
other sexually transmitted infections, including gonorrhoea, chlamydial infection and 
trichomoniasis. Prompt diagnosis and treatment of both the partners is the key for an 
effective management. 
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